RTGel™ reverse-thermal hydrogel— transformative technology for urology
When confronted with challenging conditions in urology, too often there’s no right tool for the job.
That’s why UroGen Pharma has developed RTGel, a novel technology platform designed to facilitate intracavitary treatment of challenging urological conditions.
By increasing dwell time and exposure of active drugs, RTGel has the potential to:
- Improve the therapeutic effects of urological therapies
- Increase the viability of organ-sparing techniques and give urologists a novel alternative to radical surgery
RTGel is compatible with a number of active drug products. The technology is currently being investigated in drug formulations for the treatment of low-grade upper tract urothelial carcinoma (UTUC), low-grade non–muscle-invasive bladder cancer (NMIBC), and overactive bladder (OAB).
RTGel technology is not commercially available. The safety and effectiveness of UroGen’s investigational product candidates that utilize RTGel technology have not been established.